We don’t know when. We don’t know who will get there first. But Q-day will happen — and it will change the world as we know it.
A collaborative effort has installed electronic “brains” on solar-powered robots that are 100 to 250 micrometers in size – smaller than an ant’s head – so that they can walk autonomously without being externally controlled.
Cornell researchers installed electronic “brains” on solar-powered robots that are 100 to 250 micrometers in size, so the tiny bots can walk autonomously without being externally controlled. Noël Heaney/Cornell University
While Cornell researchers and others have previously developed microscopic machines that can crawl, swim, walk and fold themselves up, there were always “strings” attached; to generate motion, wires were used to provide electrical current or laser beams had to be focused directly onto specific locations on the robots.
Facebook has taken action against a malware campaign leveraging popular topics like ChatGPT, Google BERT, and TikTok marketing tools as a lure.
The U.S. Cybersecurity and Infrastructure Security Agency (CISA) on Tuesday released an Industrial Control Systems (ICS) advisory about a critical flaw affecting ME RTU remote terminal units.
The security vulnerability, tracked as CVE-2023–2131, has received the highest severity rating of 10.0 on the CVSS scoring system for its low attack complexity.
“Successful exploitation of this vulnerability could allow remote code execution,” CISA said, describing it as a case of command injection affecting versions of INEA ME RTU firmware prior to version 3.36.
Cybersecurity researchers have uncovered weaknesses in a software implementation of the Border Gateway Protocol (BGP) that could be weaponized to achieve a denial-of-service (DoS) condition on vulnerable BGP peers.
The three vulnerabilities reside in version 8.4 of FRRouting, a popular open source internet routing protocol suite for Linux and Unix platforms. It’s currently used by several vendors like NVIDIA Cumulus, DENT, and SONiC, posing supply chain risks.
The discovery is the result of an analysis of seven different implementations of BGP carried out by Forescout Vedere Labs: FRRouting, BIRD, OpenBGPd, Mikrotik RouterOS, Juniper JunOS, Cisco IOS, and Arista EOS.
Sound waves can cross the blood-brain barrier and could deliver chemotherapy to complex and treatment-resistant glioblastomas.
Researchers have developed a new high-speed way to detect the location, size and category of multiple objects without acquiring images or requiring complex scene reconstruction. Because the new approach greatly decreases the computing power necessary for object detection, it could be useful for identifying hazards while driving.
“Our technique is based on a single-pixel detector, which enables efficient and robust multi–object detection directly from a small number of 2D measurements,” said research team leader Liheng Bian from the Beijing Institute of Technology in China. “This type of image-free sensing technology is expected to solve the problems of heavy communication load, high computing overhead and low perception rate of existing visual perception systems.”
Today’s image-free perception methods can only achieve classification, single object recognition or tracking. To accomplish all three at once, the researchers developed a technique known as image-free single-pixel object detection (SPOD). In Optics Letters, they report that SPOD can achieve an object detection accuracy of just over 80%.
High-grade gliomas functionally remodel neural circuits in the human brain, promoting tumour progression and impairing cognition.
CHICAGO, May 3 (Reuters) — An experimental Alzheimer’s drug developed by Eli Lilly and Co (LLY.N) slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.
Lilly’s drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer’s by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer’s proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death.
The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB).